• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Glycosyl compounds

Introduction to 5-Bromo-3-indolyl b-D-glucopyranoside (CAS No. 16934-09-1)

5-Bromo-3-indolyl b-D-glucopyranoside, identified by the chemical compound code CAS No. 16934-09-1, is a significant molecule in the field of pharmaceutical chemistry and bioorganic synthesis. This glycoside derivative has garnered considerable attention due to its structural complexity and its potential applications in drug development, particularly in the modulation of biological pathways involving enzymes and receptors. The compound’s unique structural features—combining an indole moiety with a glucose unit—make it a versatile scaffold for further chemical modifications and biological investigations.

The indole ring, a core structural component of many bioactive natural products, is known for its role in various biological processes, including neurotransmission and immune responses. The bromine substituent at the 5-position of the indole ring enhances the electrophilicity of the molecule, facilitating further functionalization through cross-coupling reactions or other synthetic transformations. Meanwhile, the b-D-glucopyranoside moiety introduces a hydrophilic sugar backbone, which can influence solubility, bioavailability, and interactions with biological targets.

Recent advancements in glycoscience have highlighted the importance of glycosidic linkages in drug design. 5-Bromo-3-indolyl b-D-glucopyranoside exemplifies how appending a glucose residue to an indole scaffold can modulate pharmacokinetic properties while retaining or enhancing biological activity. This approach has been particularly useful in developing orally bioavailable drugs that require efficient absorption and distribution throughout the body.

In the realm of medicinal chemistry, 5-Bromo-3-indolyl b-D-glucopyranoside serves as a valuable intermediate for synthesizing more complex derivatives. Its reactivity allows for the introduction of additional functional groups, enabling fine-tuning of its pharmacological profile. For instance, researchers have explored its use in creating novel kinase inhibitors or modulators of G-protein coupled receptors (GPCRs), which are implicated in a wide range of diseases.

One notable application of this compound has been in the study of enzyme inhibition. The indole glucoside structure can interact with enzymes such as beta-glucosidases or other hydrolases, potentially leading to the development of therapeutic agents for metabolic disorders. Additionally, its ability to cross the blood-brain barrier has made it a candidate for neuropharmacological research, particularly in investigating pathways related to neurodegenerative diseases.

The synthesis of 5-Bromo-3-indolyl b-D-glucopyranoside involves multi-step organic transformations, starting from commercially available indole derivatives and glucose precursors. Key steps include bromination at the desired position on the indole ring followed by glycosylation using protective group strategies to ensure regioselectivity. Advances in synthetic methodologies have improved yields and purity, making large-scale production more feasible for both academic and industrial applications.

From a computational chemistry perspective, molecular modeling studies have been instrumental in understanding how 5-Bromo-3-indolyl b-D-glucopyranoside interacts with biological targets. These studies have revealed insights into binding affinities, orientation preferences, and potential side effects, guiding medicinal chemists in optimizing lead structures. The integration of machine learning algorithms has further accelerated this process by predicting pharmacokinetic properties and identifying promising analogs.

The role of 5-Bromo-3-indolyl b-D-glucopyranoside in drug discovery is also underscored by its presence in several patents and clinical trials. Researchers have leveraged its structural motifs to develop candidates that exhibit antitumor, anti-inflammatory, or antimicrobial activities. While some derivatives have advanced to preclinical stages, ongoing studies continue to explore new therapeutic applications.

The environmental and regulatory considerations associated with synthesizing and handling 5-Bromo-3-indolyl b-D-glucopyranoside are also important. Despite not being classified as a hazardous material under current regulations, proper handling protocols must be followed to ensure safety during laboratory operations. Waste disposal methods must align with guidelines to minimize environmental impact.

In conclusion,5-Bromo-3-indolyl b-D-glucopyranoside (CAS No. 16934-09-1) represents a compelling example of how structural modifications can yield bioactive molecules with significant pharmaceutical potential. Its unique combination of an indole ring and glucose moiety makes it a versatile building block for drug discovery efforts aimed at addressing diverse therapeutic challenges.

• 1328-73-0(3-indoxyl-beta-d-glucopyranoside trihydrate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)